Yet another project brought in through business development fails, exposing Sumitomo’s limited pipeline.
Worries over toxicity with Pfizer's PF-06939926 halts trial dosing and could leave the way clear for its DMD rival Sarepta.
Abbvie’s swoop on Allergan looks like a case of opportunism over innovation.
Turning Point is heading into a highly competitive lung cancer niche with its lead project, which still has much to prove.
The developer of Keytruda is starting to look like a one-drug company; what must it do to avoid becoming the next Abbvie?
On sales per employee Abbvie and Bristol-Myers Squibb lead the big pharma pack, while Sanofi and Astrazeneca are the sector laggards.
G1 Therapeutics fast-tracks what it says is the first CDK4/6 inhibitor aimed at reducing chemotherapy-induced myelosuppression.
Pfizer’s Array buyout ranks as 2019’s second largest, but the price sits in a lonely space in the deal universe.